Objective: To probe into the effects of terbutaline combined with budesonide on inflammatory cytokines in children with asthma and the genetic risk factors associated with asthma. Methods: Totally 46 children with bronchial asthma admitted into our hospital from Feb. 2015 to Feb. 2017 were extracted to be randomly divided into the study group (terbutaline combined with budesonide treatment) and the control group (budesonide treatment)

with 23 cases in each group. Changes of inflammatory cytokines were observed before and after treatment. Questionnaire survey was used to collect the related disease history and family history of the children

and relevant genetic tests were performed to analyze the genetic risk factors of asthma in children. Results: The serum levels of IL-4

IL-5 and IL-17 in the study group were significantly lower than those in the control group (P<0.05)

and there was no statistically significant difference in serum levels of IFN-γ compared with the control group (P>0.05). Totally 69.57% children with asthma had family history. There were 21 cases (91.30%) of first-degree relatives with allergic diseases

and 8 cases (53.33%) of second-degree relatives with allergic diseases

the difference was statistically significant (P<0.05). The highest frequency of TT genotype (59.38%) was found in the ORMDL3 gene in children with asthma at locus rs7216389

while the frequency of TC and CC genotype was respectively 25.00% and 15.62%. Conclusion: Terbutaline combined with budesonide can reduce the levels of inflammatory cytokines in children with asthma

which is conducive to controlling the inflammatory response of trachea and improving the treatment effects. The family history of asthma

family history of allergic diseases and expression of ORMDL3 gene rs7216389-TT are genetic risk factors for asthma.